|
1
|
Selman M, Buendía-Roldán I and Pardo A:
Aging and pulmonary fibrosis. Rev Invest Clin. 68:75–83.
2016.PubMed/NCBI
|
|
2
|
Hutchinson J, Fogarty A, Hubbard R and
McKeever T: Global incidence and mortality of idiopathic pulmonary
fibrosis: A systematic review. Eur Respir J. 46:795–806. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Antoniou KM, Wuyts W, Wijsenbeek M and
Wells AU: Medical Therapy in Idiopathic Pulmonary Fibrosis. Semin
Respir Crit Care Med. 37:368–377. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lynch JP III, Huynh RH, Fishbein MC,
Saggar R, Belperio JA and Weigt SS: Idiopathic Pulmonary Fibrosis:
Epidemiology, Clinical Features, Prognosis, and Management. Semin
Respir Crit Care Med. 37:331–357. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vancheri C, Failla M, Crimi N and Raghu G:
Idiopathic pulmonary fibrosis: A disease with similarities and
links to cancer biology. Eur Respir J. 35:496–504. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Raghu G, Collard HR, Egan JJ, Martinez FJ,
Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et
al: ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis: An
official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis:
evidence-based guidelines for diagnosis and management. Am J Respir
Crit Care Med. 183:788–824. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Turgut NH, Kara H, Elagoz S, Deveci K,
Gungor H and Arslanbas E: The Protective effect of naringin against
bleomycin-induced pulmonary fibrosis in Wistar rats. Pulm Med.
2016:76013932016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Moore BB and Hogaboam CM: Murine models of
pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol.
294:L152–L160. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bonnans C, Chou J and Werb Z: Remodelling
the extracellular matrix in development and disease. Nat Rev Mol
Cell Biol. 15:786–801. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Z, Jian X, Zhang W, Wang J and Zhou
Q: Using bosentan to treat paraquat poisoning-induced acute lung
injury in rats. PLoS One. 8:e759432013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Koo HS, Kim KC and Hong YM: Gene
expressions of nitric oxide synthase and matrix metalloproteinase-2
in monocrotaline-induced pulmonary hypertension in rats after
bosentan treatment. Korean Circ J. 41:83–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Giannelli G, Iannone F, Marinosci F,
Lapadula G and Antonaci S: The effect of bosentan on matrix
metalloproteinase-9 levels in patients with systemic
sclerosis-induced pulmonary hypertension. Curr Med Res Opin.
21:327–332. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang HD, Yamaya M, Okinaga S, Jia YX,
Kamanaka M, Takahashi H, Guo LY, Ohrui T and Sasaki H: Bilirubin
ameliorates bleomycin-induced pulmonary fibrosis in rats. Am J
Respir Crit Care Med. 165:406–411. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bancroft JD and Gamble M: Connective
tissue stainsTheory and practice of histological techniques. 6th.
Elsevier Health Sciences; Churchill Livingstone: pp. 1502008
|
|
15
|
Szapiel SV, Elson NA, Fulmer JD,
Hunninghake GW and Crystal RG: Bleomycin-induced interstitial
pulmonary disease in the nude, athymic mouse. Am Rev Respir Dis.
120:893–899. 1979.PubMed/NCBI
|
|
16
|
Sleijfer S: Bleomycin-induced pneumonitis.
Chest. 120:617–624. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhou XM, Zhang GC, Li JX and Hou J:
Inhibitory effects of Hu-qi-yin on the bleomycin-induced pulmonary
fibrosis in rats. J Ethnopharmacol. 111:255–264. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Araz O, Demirci E, Ucar E Yilmazel, Calik
M, Pulur D, Karaman A, Yayla M, Altun E, Halici Z and Akgun M:
Comparison of reducing effect on lung injury of dexamethasone and
bosentan in acute lung injury: An experimental study. Multidiscip
Respir Med. 8:74–81. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Watson WH, Ritzenthaler JD and Roman J:
Lung extracellular matrix and redox regulation. Redox Biol.
8:305–315. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Teixeira KC, Soares FS, Rocha LG, Silveira
PC, Silva LA, Valença SS, Dal Pizzol F, Streck EL and Pinho RA:
Attenuation of bleomycin-induced lung injury and oxidative stress
by N-acetylcysteine plus deferoxamine. Pulm Pharmacol Ther.
21:309–316. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liang X, Tian Q, Wei Z, Liu F, Chen J,
Zhao Y, Qu P, Huang X, Zhou X, Liu N, et al: Effect of Feining on
bleomycin-induced pulmonary injuries in rats. J Ethnopharmacol.
134:971–976. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Arafa HM, AbdelWahab MH, ElShafeey MF,
Badary OA and Hamada FM: Anti-fibrotic effect of meloxicam in a
murine lung fibrosis model. Eur J Pharmacol. 564:181–189. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yoon JS, Chae MK, Jang SY, Lee SY and Lee
EJ: Antifibrotic effects of quercetin in primary orbital
fibroblasts and orbital fat tissue cultures of Graves' orbitopathy.
Invest Ophthalmol Vis Sci. 53:5921–5929. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
King TE Jr, Pardo A and Selman M:
Idiopathic pulmonary fibrosis. Lancet. 378:1949–1961. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pardo A, Cabrera S, Maldonado M and Selman
M: Role of matrix metalloproteinases in the pathogenesis of
idiopathic pulmonary fibrosis. Respir Res. 17:232016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pardo A and Selman M: Matrix
metalloproteases in aberrant fibrotic tissue remodeling. Proc Am
Thorac Soc. 3:383–388. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Selman M, Ruiz V, Cabrera S, Segura L,
Ramírez R, Barrios R and Pardo A: TIMP-1, −2, −3, and −4 in
idiopathic pulmonary fibrosis. A prevailing nondegradative lung
microenvironment? Am J Physiol Lung Cell Mol Physiol.
279:L562–L574. 2000.PubMed/NCBI
|
|
28
|
Ramos C, Montaño M, García-Alvarez J, Ruiz
V, Uhal BD, Selman M and Pardo A: Fibroblasts from idiopathic
pulmonary fibrosis and normal lungs differ in growth rate,
apoptosis, and tissue inhibitor of metalloproteinases expression.
Am J Respir Cell Mol Biol. 24:591–598. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zuo F, Kaminski N, Eugui E, Allard J,
Yakhini Z, BenDor A, Lollini L, Morris D, Kim Y, DeLustro B, et al:
Gene expression analysis reveals matrilysin as a key regulator of
pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA.
99:6292–6297. 2002. View Article : Google Scholar : PubMed/NCBI
|
